source
- FDA approves Roivant's brepocitinib for rare autoimmune disease dermatomyositisOn Thursday the U.S. Food and Drug Administration gave its nod to a new therapy from Roivant Sciences and its subsidiary Priovant. The oral medication, brepocitinib, will be sold under the brand na…
- CMS GLP-1 pilot shows early uptake and health benefits for seniors, signaling broader weight-loss drug accessCMS launched a federal pilot program to expand access to GLP-1 weight-loss medications for seniors. After about two months, early data show that enrollment is rising and participants report improv…